Pathological Effects of Prostate Cancer Correlate With Neuroendocrine Differentiation and PTEN Expression After Bicalutamide Monotherapy

Journal of Urology

Volumn 182, Issue 4 SUPPL., 2009, Pages 1378-1384

  Ham, Won Sik ^a   Cho, Nam Hoon ^a   Kim, Won Tae ^a   Ju, Hee Jeong ^a   Lee, Jin Sun ^a   Choi, Young Deuk ^a  

^a Urological Science Institute   (South Korea)

Author keywords

bicalutamide; epidermal growth factor; prostatic neoplasms; PTEN phosphohydrolase; treatment failure

Indexed keywords

BICALUTAMIDE; CHROMOGRANIN A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SEMINAL VESICLE; TUMOR VOLUME;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; HUMANS; MALE; MIDDLE AGED; NITRILES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; TOSYL COMPOUNDS;

EID: 69749104279     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.06.025     Document Type: Article

References (21)

1. Garnick M.B., Glode L.M., and Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311 (1984) 1281
2. Lee J.T., Steelman L.S., and McCubrey J.A. Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64 (2004) 8397
3. Chen M.L., Xu P.Z., Peng X.D., et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten mice. Genes Dev 20 (2006) 1569
4. Osman I., Scher H.I., Drobnjak M., et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7 (2001) 2643
5. Shi Y., Brands F.H., Chatterjee S., et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 166 (2001) 1514
6. Vashchenko N., and Abrahamsson P.A. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 47 (2005) 147
7. Evangelou A.I., Winter S.F., Huss W.J., et al. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 91 (2004) 671
8. Bertram J., Peacock J.W., Fazli L., et al. Loss of PTEN is associated with progression to androgen independence. Prostate 66 (2006) 895
9. Wu X., Senechal K., Neshat M.S., et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95 (1998) 15587
10. Moscatello D.K., Holgado-Madruga M., Emlet D.R., et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273 (1998) 200
11. Berger R., Lin D.I., Nieto M., et al. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 66 (2006) 5723
12. Wu C., and Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 282 (2007) 3571
13. Wellington K., and Keam S.J. Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer. Drugs Aging 24 (2007) 169
14. Reuter V.E. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49 (1997) 16
15. Böcking A., and Auffermann W. Cytological grading of therapy-induced tumor regression in prostatic carcinoma: proposal of a new system. Diagn Cytopathol 3 (1987) 108
16. Helpap B. Treated prostatic carcinoma. Histological, immunohistochemical and cell kinetic studies. Appl Pathol 3 (1985) 230
17. Festuccia C., Gravina G.L., Muzi P., et al. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Endocr Relat Cancer 14 (2007) 601
18. Pendleton J., Pisters L.L., Nakamura K., et al. Neoadjuvant therapy before radical prostatectomy: where have we been?. Where are we going?. Urol Oncol 25 (2007) 11
19. Li L., Ittmann M.M., Ayala G., et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 8 (2005) 108
20. Majumder P.K., and Sellers W.R. Akt-regulated pathways in prostate cancer. Oncogene 24 (2005) 7465
21. Di Lorenzo G., Tortora G., D'Armiento F.P., et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8 (2002) 3438